QNCX Quince Therapeutics Forecast, Technical & Fundamental Analysis

QNCX sees its Stochastic Oscillator recovers from oversold territory

On September 02, 2025, the Stochastic Oscillator for QNCX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 57 instances where the indicator left the oversold zone. In of the 57 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Technical Analysis (Indicators)

Bullish Trend Analysis

The 50-day moving average for QNCX moved above the 200-day moving average on July 31, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 04, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on QNCX as a result. In of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

QNCX moved below its 50-day moving average on August 21, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for QNCX crossed bearishly below the 50-day moving average on August 26, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where QNCX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for QNCX entered a downward trend on August 20, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. QNCX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.369) is normal, around the industry mean (20.013). P/E Ratio (0.000) is within average values for comparable stocks, (51.928). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.122). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (326.881).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QNCX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.